» Articles » PMID: 33206391

3D Hydrogels Reveal Medulloblastoma Subgroup Differences and Identify Extracellular Matrix Subtypes That Predict Patient Outcome

Overview
Journal J Pathol
Specialty Pathology
Date 2020 Nov 18
PMID 33206391
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Medulloblastoma (MB) is the most common malignant brain tumour in children and is subdivided into four subgroups: WNT, SHH, Group 3, and Group 4. These molecular subgroups differ in their metastasis patterns and related prognosis rates. Conventional 2D cell culture methods fail to recapitulate these clinical differences. Realistic 3D models of the cerebellum are therefore necessary to investigate subgroup-specific functional differences and their role in metastasis and chemoresistance. A major component of the brain extracellular matrix (ECM) is the glycosaminoglycan hyaluronan. MB cell lines encapsulated in hyaluronan hydrogels grew as tumour nodules, with Group 3 and Group 4 cell lines displaying clinically characteristic laminar metastatic patterns and levels of chemoresistance. The glycoproteins, laminin and vitronectin, were identified as subgroup-specific, tumour-secreted ECM factors. Gels of higher complexity, formed by incorporation of laminin or vitronectin, revealed subgroup-specific adhesion and growth patterns closely mimicking clinical phenotypes. ECM subtypes, defined by relative levels of laminin and vitronectin expression in patient tissue microarrays and gene expression data sets, were able to identify novel high-risk MB patient subgroups and predict overall survival. Our hyaluronan model system has therefore allowed us to functionally characterize the interaction between different MB subtypes and their environment. It highlights the prognostic and pathological role of specific ECM factors and enables preclinical development of subgroup-specific therapies. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Citing Articles

Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level.

Godbole S, Voss H, Gocke A, Schlumbohm S, Schumann Y, Peng B Nat Commun. 2024; 15(1):6237.

PMID: 39043693 PMC: 11266559. DOI: 10.1038/s41467-024-50554-z.


The importance of 3D fibre architecture in cancer and implications for biomaterial model design.

Ashworth J, Cox T Nat Rev Cancer. 2024; 24(7):461-479.

PMID: 38886573 DOI: 10.1038/s41568-024-00704-8.


Applications of 3D Bioprinting Technology to Brain Cells and Brain Tumor Models: Special Emphasis to Glioblastoma.

Ozbek I, Saybasili H, Ulgen K ACS Biomater Sci Eng. 2024; 10(5):2616-2635.

PMID: 38664996 PMC: 11094688. DOI: 10.1021/acsbiomaterials.3c01569.


Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules.

Bibbo F, Asadzadeh F, Boccia A, Sorice C, Bianco O, Sacca C Int J Mol Sci. 2024; 25(7).

PMID: 38612726 PMC: 11011515. DOI: 10.3390/ijms25073917.


Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging.

Linke F, Johnson J, Kern S, Bennett C, Lourdusamy A, Lea D Acta Neuropathol Commun. 2023; 11(1):6.

PMID: 36631900 PMC: 9835248. DOI: 10.1186/s40478-022-01496-4.


References
1.
Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

2.
Coluccia D, Figuereido C, Isik S, Smith C, Rutka J . Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm. Curr Neurol Neurosci Rep. 2016; 16(5):43. DOI: 10.1007/s11910-016-0644-7. View

3.
Ellison D, Kocak M, Dalton J, Megahed H, Lusher M, Ryan S . Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2010; 29(11):1400-7. PMC: 3525837. DOI: 10.1200/JCO.2010.30.2810. View

4.
Zeltzer P, Boyett J, Finlay J, Albright A, RORKE L, Milstein J . Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999; 17(3):832-45. DOI: 10.1200/JCO.1999.17.3.832. View

5.
Hynes W, Doty N, Zarembinski T, Schwartz M, Toepke M, Murphy W . Micropatterning of 3D Microenvironments for Living Biosensor Applications. Biosensors (Basel). 2014; 4(1):28-44. PMC: 4004032. DOI: 10.3390/bios4010028. View